Clinical significance of quantitative HER2 gene amplification as related to its predictive value in breast cancer patients in neoadjuvant setting

OncoTargets and Therapy
Ziping WuJinsong Lu

Abstract

The aims of this study were to determine whether the quantitative HER2 gene amplification level is related to the key clinicopathological features that represent the aggressiveness of breast cancer (BC) and to determine whether the quantitative HER2 gene amplification level could predict the treatment response in the subset of HER2-positive patients who received neoadjuvant targeted therapy. Patients treated with weekly cisplatin- and paclitaxel-based neoadjuvant chemotherapy, who had undergone both immunohistochemistry and the fluorescence in situ hybridization test for HER2, were included in the study (n=103). For HER2-positive patients, defined as immunohistochemistry score 3+ or fluorescence in situ hybridization ratio ≥2.0, trastuzumab was recommended with neoadjuvant chemotherapy (n=45). Pathological complete response was defined as complete pathological remission of tumor cells both in breast and axillary lymph nodes postoperation. In all patients enrolled in the study, a higher HER2 amplification level was significantly correlated with larger tumor size and the absence of ER and PR expression. In HER2-positive patients treated with neoadjuvant trastuzumab concurrent with chemotherapy, both univariate and multivariate lo...Continue Reading

Citations

Oct 4, 2018·Cancer Cytopathology·Heba W Z Khella, George M Yousef
Jan 23, 2021·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Mohamed AlhamarDhananjay A Chitale
Aug 17, 2021·Annales de pathologie·Camille FranchetUNKNOWN Pour le GEFPICS

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy

Clinical Trials Mentioned

NCT02199418
NCT02221999

Software Mentioned

STATA Statistics SE

Related Concepts

© 2022 Meta ULC. All rights reserved